Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected~* Received pre- and post-test counseling at the GHESKIO Centers~* CD4 count between 200 and 350 cells/mm3~* World Health Organization (WHO) Stage I, II, or III HIV disease~* Willing to use acceptable forms of contraception~Exclusion Criteria:~* WHO Stage IV HIV disease (AIDS)~* 7 or more days of cumulative ART prior to study entry OR on ART at time of study entry~* Active TB, if diagnostic work-up for TB is incomplete OR if decision to treat TB has not been made. More information on this criterion can be found in the protocol.~* Recurrent active TB OR history of interrupted or incomplete TB therapy. More information on this criterion can be found in the protocol.~* Has not been evaluated for latent TB and decision to treat latent TB with isoniazid has not been made. More information on this criterion can be found in the protocol.~* Requires ART in the next 3 months, in the opinion of the investigator~* Other serious medical illness requiring chronic maintenance therapy (e.g., hypertension, diabetes) UNLESS the individual has completed at least 14 days of therapy prior to study enrollment AND is clinically stable~* Any psychological condition (e.g., severe depression, schizophrenia) that, in the opinion of the investigator, may interfere with the study~* Any social condition (e.g., pending emigration, pending incarceration) that, in the opinion of the investigator, may interfere with the study~* Active drug or alcohol use that, in the opinion of the investigator, may interfere with the study~* Current inflammation of the pancreas~* Allergy/sensitivity to any of study drugs or their formulations~* Requires certain medications~* Enrolled in another therapeutic or interventional clinical trial~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Randomly assigned group who will start an ART regimen of 3TC/ZDV and EFV twice daily at study entry
- B (Type: ACTIVE_COMPARATOR): Randomly assigned group who will delay beginning ART regimen of 3TC/ZDV and EFC twice daily until they develop clinical AIDS or their CD4 count drops below 200 cells/mm3

Based on this trial design, predict the completion outcome and termination type (if applicable).